JP2020509043A - カンナビノイドアゴニストによる認知症の治療 - Google Patents

カンナビノイドアゴニストによる認知症の治療 Download PDF

Info

Publication number
JP2020509043A
JP2020509043A JP2019547448A JP2019547448A JP2020509043A JP 2020509043 A JP2020509043 A JP 2020509043A JP 2019547448 A JP2019547448 A JP 2019547448A JP 2019547448 A JP2019547448 A JP 2019547448A JP 2020509043 A JP2020509043 A JP 2020509043A
Authority
JP
Japan
Prior art keywords
dementia
compound
use according
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019547448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509043A5 (cg-RX-API-DMAC10.html
Inventor
プエルタス、ラファエル ロドリゲス
プエルタス、ラファエル ロドリゲス
ビセンテ、イバン マヌエル
ビセンテ、イバン マヌエル
イトゥリサガ、ラウラ ロンバルデロ
イトゥリサガ、ラウラ ロンバルデロ
オベヘロ、アルベルト ジョレンテ
オベヘロ、アルベルト ジョレンテ
ロドリゲス、マルタ モレノ
ロドリゲス、マルタ モレノ
ガルデアサバル、ホナタン マルティネス
ガルデアサバル、ホナタン マルティネス
デ サン ロマン マルティン、エスティバリス ゴンザレス
デ サン ロマン マルティン、エスティバリス ゴンザレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of the Basque Country
Original Assignee
University of the Basque Country
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of the Basque Country filed Critical University of the Basque Country
Publication of JP2020509043A publication Critical patent/JP2020509043A/ja
Publication of JP2020509043A5 publication Critical patent/JP2020509043A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019547448A 2017-03-02 2018-02-23 カンナビノイドアゴニストによる認知症の治療 Pending JP2020509043A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201730284A ES2638057B1 (es) 2017-03-02 2017-03-02 Tratamiento de la demencia con agonistas cannabinoides
ESP201730284 2017-03-02
PCT/EP2018/054525 WO2018158150A1 (en) 2017-03-02 2018-02-23 Treatment of dementia with cannabinoid agonists

Publications (2)

Publication Number Publication Date
JP2020509043A true JP2020509043A (ja) 2020-03-26
JP2020509043A5 JP2020509043A5 (cg-RX-API-DMAC10.html) 2021-04-08

Family

ID=60043443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019547448A Pending JP2020509043A (ja) 2017-03-02 2018-02-23 カンナビノイドアゴニストによる認知症の治療

Country Status (5)

Country Link
US (1) US20200016163A1 (cg-RX-API-DMAC10.html)
EP (1) EP3589322A1 (cg-RX-API-DMAC10.html)
JP (1) JP2020509043A (cg-RX-API-DMAC10.html)
ES (1) ES2638057B1 (cg-RX-API-DMAC10.html)
WO (1) WO2018158150A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022512409A (ja) 2018-12-14 2022-02-03 ナチュラル イクストゥラクション システムズ，エルエルシー アニオン性カンナビノイド分子と関連する組成物および方法
WO2021084523A2 (en) * 2019-10-31 2021-05-06 Radient Technologies Innovations Inc. Enhancing lifestyle of memory impaired patients using cbd
WO2021097163A1 (en) * 2019-11-14 2021-05-20 Natural Extraction Systems, LLC Pharmaceutical compositions comprising cannabinoid anions
WO2022026960A1 (en) 2020-07-31 2022-02-03 Natural Extraction Systems, LLC Compositions and methods related to excipients and cannabinoid formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
PL2606032T3 (pl) * 2010-08-20 2015-07-31 Univ Washington Through Its Center For Commercialization Kompozycja i sposoby terapii glejakaep

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF PHARMACOLOGY, vol. 171, JPN6021045054, 2014, pages 468 - 479, ISSN: 0004798433 *
MOLECULAR PHARMACOLOGY, vol. 79, JPN6021045056, 2011, pages 964 - 973, ISSN: 0004798432 *
THE JOURNAL OF NEUROSCIENCE, vol. 25, no. 8, JPN6021045057, 2005, pages 1904 - 1913, ISSN: 0004798431 *

Also Published As

Publication number Publication date
ES2638057B1 (es) 2018-10-01
US20200016163A1 (en) 2020-01-16
EP3589322A1 (en) 2020-01-08
ES2638057A1 (es) 2017-10-18
WO2018158150A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
JP2609968B2 (ja) グリシン／ｎｍｄａ受容体複合体の機能性拮抗剤による情緒障害の治療
EP1272218B1 (en) A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
US6369052B1 (en) Combination of huperzine and nicotinic compounds as a neuroprotective agent
CN101466366A (zh) 用于治疗认知障碍的α-氨基酰胺衍生物
OA12554A (en) Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders.
JP2017503765A (ja) ガバペンチノイドおよびシグマ受容体の組み合わせ
KR20200026925A (ko) 스타틴 조성물 및 시누클레인병변 치료에 사용하는 방법
US20200016163A1 (en) Treatment of dementia with cannabinoid agonists
US11160798B2 (en) Neuroprotective CB2 receptor agonists
US12194033B2 (en) Glycine receptor modulators and methods of use
US20150258112A1 (en) Methods and compositions for treating depression using ibogaine
JP5223859B2 (ja) 神経因性疼痛新規予防剤及び／又は治療剤
JP2005507411A (ja) 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。
US7049334B2 (en) Enhancement of learning and memory and treatment of amnesia
WO2024028611A1 (en) Oxadiazole compounds for use in the treatment of obsessive compulsive disorder
US20060189612A1 (en) Pharmaceutically active morpholinol
KR20000029647A (ko) 양극성장애의치료방법
JP2008524236A (ja) エストロゲンβアゴニストについての新規用途
WO2026077305A1 (zh) 一种预防或治疗神经系统变性疾病的方法和药物组合
JP2019524794A (ja) ヒスタミン−３受容体インバースアゴニストとアセチルコリンエステラーゼ阻害剤との組合せ
Luthra et al. Intravenous Anesthetic Agents
ES3062815T3 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
US20070191365A1 (en) 3,4,6-Substituted pyridazines for treating neuropathic pain and associated syndromes
Leung et al. The Role of Ketamine in Treatment of Complex Regional Pain Syndrome: A review of current evidence

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210224

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220614